AbbVie acquires Landos Biopharma for up to $212 million to expand its immune system medicine pipeline, including NX-13 for ulcerative colitis.
AbbVie to acquire Landos Biopharma for up to $212 million, aiming to expand its pipeline of medicines for immune system-related illnesses. Landos is conducting a mid-stage clinical study of its lead experimental drug, NX-13, for ulcerative colitis. AbbVie will acquire Landos for $20.42 per share in cash, totaling approximately $137.5 million, with an additional up to $11.14 per share, or about $75 million, contingent on certain clinical development milestones. The acquisition is expected to close in the second quarter of 2024.
March 25, 2024
16 Articles